PDF herunterladen
Int J Angiol
DOI: 10.1055/s-0044-1791505
Case Report

Thromboangiitis Obliterans (Buerger's Disease): A Young Woman's Rare Case and Current Knowledge

Giuliana Autiero
1   Department of Internal Medicine, Ospedale dell'Angelo, Mestre-Venezia, Italy
,
Anna Padovan
1   Department of Internal Medicine, Ospedale dell'Angelo, Mestre-Venezia, Italy
,
Francesca Vittone
1   Department of Internal Medicine, Ospedale dell'Angelo, Mestre-Venezia, Italy
,
Elisabetta Grolla
2   Department of Cardiology, Ospedale dell'Angelo, Mestre-Venezia, Italy
,
Michele Dalla Vestra
3   Department of Internal Medicine, Angiology Unit, Ospedale dell'Angelo, Mestre-Venezia, Italy
› Institutsangaben Funding None.
› Weitere Informationen
    Lizenzen und Reprints

Abstract

In this paper, we described the clinical features and the typical vascular imaging picture of a rare case of thromboangiitis obliterans (TAO) in a 47-year-old, young, Caucasian woman without relevant medical records except for smoking habits and admitted to our Department of Internal Medicine with a necrotic lesion of the first and third toes of the right foot. After a rapid clinical and instrumental evaluation, necrotic tissue debridement was performed and the patient was treated with Iloprost infusion and antibiotics (for overlapping infection) with clinical improvement. Moreover, we summarized the current knowledge about the disease making an update and critical examination of the literature. TAO, also known as Buerger's disease, is a rare disease. In recent decades, the incidence of TAO has decreased in Europe and the United States in men but several studies have reported an increase in the prevalence of disease in women. TAO is a segmental nonatherosclerotic inflammatory disorder that involves primarily small and medium arteries, veins, and nerves of the extremities with limb ischemia, pain, claudication, ulcers, and necrosis that can lead to amputation. Smoking is considered the main risk factor, but despite that, more than 100 years have passed since the first description of the disease by Leo Buerger, and knowledge on pathogenesis, precipitating factors, and therapy remain still unclear.

Keywords

thromboangiitis obliterans - Buerger's disease - peripheral artery disease - young woman


Publikationsverlauf

Artikel online veröffentlicht:
27. September 2024

© 2024. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 von Winiwarter F. Uber eine Eigenthumliche Form von Endarteriitis und Endophlebitis mit Gangan des Fusses. Arch Kiln Chir 1878; 23: 202-226
    PubMedSuche in Google Scholar
  • 2 Buerger L. Thromboangiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene. Am J Med Sci 1908; 136: 567-580
    CrossrefPubMedSuche in Google Scholar
  • 3 Arkkila PE. Thromboangiitis obliterans (Buerger's disease). Orphanet J Rare Dis 2006; 1: 14
    CrossrefPubMedSuche in Google Scholar
  • 4 Gallagher KA, Tracci MC, Scovell SD. Vascular arteritides in women. J Vasc Surg 2013; 57 (4 suppl): 27S-36S
    CrossrefPubMedSuche in Google Scholar
  • 5 Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 2000; 343 (12) 864-869
    CrossrefPubMedSuche in Google Scholar
  • 6 Cooper LT, Tse TS, Mikhail MA, McBane RD, Stanson AW, Ballman KV. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease). J Am Coll Cardiol 2004; 44 (12) 2410-2411
    CrossrefPubMedSuche in Google Scholar
  • 7 Batsis JA, Casey KK. Thromboangiitis obliterans (Buerger disease). Mayo Clin Proc 2007; 82 (04) 448
    CrossrefPubMedSuche in Google Scholar
  • 8 Lie JT. The rise and fall and resurgence of thromboangiitis obliterans (Buerger's disease). Acta Pathol Jpn 1989; 39 (03) 153-158
    PubMedSuche in Google Scholar
  • 9 Shionoya S, Leu H, Lie J. Buerger's disease (thromboangiitis obliterans). Vasc Surg 1995; 4: 235-245
    PubMedSuche in Google Scholar
  • 10 Hida N, Ohta T. Current status of patients with Buerger disease in Japan. Ann Vasc Dis 2013; 6 (03) 617-623
    CrossrefPubMedSuche in Google Scholar
  • 11 Wysokinski WE, Kwiatkowska W, Sapian-Raczkowska B, Czarnacki M, Doskocz R, Kowal-Gierczak B. Sustained classic clinical spectrum of thromboangiitis obliterans (Buerger's disease). Angiology 2000; 51 (02) 141-150
    CrossrefPubMedSuche in Google Scholar
  • 12 Fleshman K. Buerger's disease in Nepal. Trop Doct 1998; 28 (04) 203-206
    CrossrefPubMedSuche in Google Scholar
  • 13 Mills JL, Porter JM. Buerger's disease (thromboangiitis obliterans). Ann Vasc Surg 1991; 5 (06) 570-572
    CrossrefPubMedSuche in Google Scholar
  • 14 Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 1990; 82 (5, suppl) IV3-IV8
    PubMedSuche in Google Scholar
  • 15 Zheng JF, Chen YM, Chen DY, Lin CH, Chen HH. The incidence and prevalence of thromboangiitis obliterans in Taiwan: a nationwide, population-based analysis of data collected from 2002 to 2011. Clinics (Sao Paulo) 2016; 71 (07) 399-403
    CrossrefPubMedSuche in Google Scholar
  • 16 Sasaki S, Sakuma M, Kunihara T, Yasuda K. Current trends in thromboangiitis obliterans (Buerger's disease) in women. Am J Surg 1999; 177 (04) 316-320
    CrossrefPubMedSuche in Google Scholar
  • 17 Liew NC, Lee L, Nor Hanipah Z, Gee T, Jabar MF. Pathogenesis and management of Buerger's disease. Int J Low Extrem Wounds 2015; 14 (03) 231-235
    CrossrefPubMedSuche in Google Scholar
  • 18 Ohta T, Ishioashi H, Hosaka M, Sugimoto I. Clinical and social consequences of Buerger disease. J Vasc Surg 2004; 39 (01) 176-180
    CrossrefPubMedSuche in Google Scholar
  • 19 Chen Q, Chen J, Li J, Cheng Y, Zhang R, Liu Z. Recent advances of oxidative stress in thromboangiitis obliterans: biomolecular mechanisms, biomarkers, sources and clinical applications. Thromb Res 2023; 230: 64-73
    CrossrefPubMedSuche in Google Scholar
  • 20 Małecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century–a new face of disease. Atherosclerosis 2009; 206 (02) 328-334
    CrossrefPubMedSuche in Google Scholar
  • 21 Pavlic V, Vujic-Aleksic V, Zubovic N, Gojkov-Vukelic M. Periodontitis and Buerger's disease: recent advances. Acta Inform Med 2013; 21 (04) 250-252
    CrossrefPubMedSuche in Google Scholar
  • 22 Chen YW, Nagasawa T, Wara-Aswapati N. et al. Association between periodontitis and anti-cardiolipin antibodies in Buerger disease. J Clin Periodontol 2009; 36 (10) 830-835
    CrossrefPubMedSuche in Google Scholar
  • 23 Iwai T, Inoue Y, Umeda M. et al. Oral bacteria in the occluded arteries of patients with Buerger disease. J Vasc Surg 2005; 42 (01) 107-115
    CrossrefPubMedSuche in Google Scholar
  • 24 Kubota T, Inoue Y, Iwai T, Kurihara N, Huang Y, Umeda M. Arterial thrombosis after intravenous infusion of oral bacterium in a rat model. Ann Vasc Surg 2008; 22 (03) 412-416
    CrossrefPubMedSuche in Google Scholar
  • 25 Piazza G, Creager MA. Thromboangiitis obliterans. Circulation 2010; 121 (16) 1858-1861
    CrossrefPubMedSuche in Google Scholar
  • 26 Shapouri-Moghaddam A, Saeed Modaghegh MH, Rahimi HR, Ehteshamfar SM, Tavakol Afshari J. Molecular mechanisms regulating immune responses in thromboangiitis obliterans: A comprehensive review. Iran J Basic Med Sci 2019; 22 (03) 215-224
    PubMedSuche in Google Scholar
  • 27 Ketha SS, Cooper LT. The role of autoimmunity in thromboangiitis obliterans (Buerger's disease). Ann N Y Acad Sci 2013; 1285: 15-25
    CrossrefPubMedSuche in Google Scholar
  • 28 Berlit P, Kessler C, Reuther R, Krause KH. New aspects of thromboangiitis obliterans (von Winiwarter-Buerger's disease). Eur Neurol 1984; 23 (06) 394-399
    CrossrefPubMedSuche in Google Scholar
  • 29 Klein-Weigel PF, Richter JG. Thromboangiitis obliterans (Buerger's disease). Vasa 2014; 43 (05) 337-346
    CrossrefPubMedSuche in Google Scholar
  • 30 Javierre BM, Burren OS, Wilder SP. et al; BLUEPRINT Consortium. Lineage-specific genome architecture links enhancers and non-coding disease variants to target gene promoters. Cell 2016; 167 (05) 1369-1384.e19
    CrossrefPubMedSuche in Google Scholar
  • 31 Chen Z, Takahashi M, Naruse T. et al. Synergistic contribution of CD14 and HLA loci in the susceptibility to Buerger disease. Hum Genet 2007; 122 (3-4): 367-372
    CrossrefPubMedSuche in Google Scholar
  • 32 Shi ZF, Fang QB, Limu S, Jiareke T, Ge XH. Association between three SNPs and thromboangiitis obliterans in Xinjiang Uyghur population. Genet Test Mol Biomarkers 2016; 20 (02) 55-62
    CrossrefPubMedSuche in Google Scholar
  • 33 Sasaki S, Sakuma M, Yasuda K. Current status of thromboangiitis obliterans (Buerger's disease) in Japan. Int J Cardiol 2000; 75 (Suppl. 01) S175-S181
    CrossrefPubMedSuche in Google Scholar
  • 34 Ates A, Yekeler I, Ceviz M. et al. One of the most frequent vascular diseases in northeastern of Turkey: thromboangiitis obliterans or Buerger's disease (experience with 344 cases). Int J Cardiol 2006; 111 (01) 147-153
    CrossrefPubMedSuche in Google Scholar
  • 35 Shionoya S. What is Buerger's disease?. World J Surg 1983; 7 (04) 544-551
    CrossrefPubMedSuche in Google Scholar
  • 36 Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg 1996; 11 (03) 335-339
    CrossrefPubMedSuche in Google Scholar
  • 37 De Haro J, Acin F, Bleda S, Varela C, Esparza L. Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan. BMC Cardiovasc Disord 2012; 12: 5
    CrossrefPubMedSuche in Google Scholar
  • 38 The European TAO Study Group. Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. Eur J Vasc Endovasc Surg 1998; 15 (04) 300-307
    CrossrefPubMedSuche in Google Scholar
  • 39 Bozkurt AK, Köksal C, Demirbas MY. et al; Turkish Buerger's Disease Research Group. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. Int Angiol 2006; 25 (02) 162-168
    PubMedSuche in Google Scholar
  • 40 De Haro J, Bleda S, Acin F. An open-label study on long-term outcomes of bosentan for treating ulcers in thromboangiitis obliterans (Buerger's disease). Int J Cardiol 2014; 177 (02) 529-531
    CrossrefPubMedSuche in Google Scholar
  • 41 Boda Z, Udvardy M, Rázsó K. et al. Stem cell therapy: a promising and prospective approach in the treatment of patients with severe Buerger's disease. Clin Appl Thromb Hemost 2009; 15 (05) 552-560
    CrossrefPubMedSuche in Google Scholar
  • 42 Heo SH, Park YS, Kang ES. et al. Early results of clinical application of autologous whole bone marrow stem cell transplantation for critical limb ischemia with Buerger's disease. Sci Rep 2016; 6: 19690
    CrossrefPubMedSuche in Google Scholar
  • 43 Donas KP, Schulte S, Ktenidis K, Horsch S. The role of epidural spinal cord stimulation in the treatment of Buerger's disease. J Vasc Surg 2005; 41 (05) 830-836
    CrossrefPubMedSuche in Google Scholar
  • 44 Sasajima T, Kubo Y, Inaba M, Goh K, Azuma N. Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. Eur J Vasc Endovasc Surg 1997; 13 (02) 186-192
    CrossrefPubMedSuche in Google Scholar
  • 45 Graziani L, Morelli L, Parini F. et al. Clinical outcome after extended endovascular recanalization in Buerger's disease in 20 consecutive cases. Ann Vasc Surg 2012; 26 (03) 387-395
    CrossrefPubMedSuche in Google Scholar
  • 46 Yuan L, Li Z, Bao J, Jing Z. Endovascular SilverHawk directional atherectomy for thromboangiitis obliterans with occlusion of the popliteal artery. Ann Vasc Surg 2014; 28 (04) 1037.e11-1037.e14
    CrossrefPubMedSuche in Google Scholar